Bad Faith Required For Preliminary Injunction Against Patent Holder Warning Potential Infringers
Client Alert | 1 min read | 04.14.08
In Judkins v. HT Window Fashion Corp. (No. 2007-1434; April 8, 2008), a Federal Circuit panel affirms a district court's denial of a preliminary injunction for an alleged violation of section 43(a) of the Lanham Act which was filed as a counterclaim in response to a claim for patent infringement. HT Window Fashion alleged that Judkins, the patent holder, sent their customers letters stating that HT Window Fashion infringed his patents in bad faith because the Judkins purportedly knew that the patent was unenforceable. The panel agrees that the Judkins' actions did not rise to the level of bad faith for HT Window Fashion to prevail on the section 43(a) claim stemming from a patentee's marketplace activity in support of his patent. Bad faith, in the context of informing potential infringers of a patent and potentially infringing activity, requires that no reasonable litigant could realistically expect to prevail in a dispute over infringement of the patent. In affirming the denial of a preliminary injunction, the Federal Circuit finds that the most significant factor for determining whether a party is entitled to an injunction is the likelihood that the moving party would succeed on the merits. The district's courts reliance on the patent's presumption of validity, even in view of the possibility of inequitable conduct, is not found to be an abuse of discretion.
Contacts
Insights
Client Alert | 4 min read | 08.29.25
Gender-Affirming Care Targeted for Potential False Claims Act Enforcement
On August 19, 2025, the Office of Personnel Management (OPM) informed insurers participating in the Federal Employees Health Benefits or Postal Service Health Benefits programs that gender-affirming care would no longer be covered for federal workers starting in 2026. This coverage decision is the Trump Administration’s latest action stemming from Executive Order 14187 which aims to prevent certain treatments, such as gender-affirming hormone therapy, surgeries, and puberty blockers for those under the age of 19. As previously discussed, the Administration has also signaled its intent to use various law enforcement tools against gender-affirming care, including Section 5 of the Federal Trade Commission Act to police false or unsupported claims by medical professionals about gender-affirming treatments.
Client Alert | 4 min read | 08.28.25
9th Circuit Marches Forward to the Future Finding Digital Assets Are Protected Under Trademark Law
Client Alert | 2 min read | 08.27.25
CPSC Maintains Momentum on eFiling Requirements for Consumer Products
Client Alert | 10 min read | 08.27.25
The New EU “Pharma Package”: Advertising – A Comparison of Commission/Parliament/Council Positions